Jacobio Pharmaceuticals Group (HKG:1167) said the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approved its Investigational New Drug (IND) application of its cancer drug JAB-23E73, according to a Thursday filing with the Hong Kong bourse.
The drug's IND application was previously approved by US FDA, and also plans to initiate the Phase I/IIA clinical trial in advanced solid tumor patients in China and the US.
The pharmaceutical stocks were up by almost 3% in recent trading.
Price (HKD): $1.77, Change: $+0.030, Percent Change: +1.72%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。